Cargando…

Reversibility of the malignant phenotype in monoclonal tumours in the mouse.

Longterm goitrogen administration to rodents is well known to result in multiple proliferative lesions of the thyroid. The regression of these lesions on withdrawal of goitrogen has led to their neoplastic nature being questioned, and they have been regarded as 'nodules' rather than as tru...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, G. A., Williams, D., Williams, E. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971777/
https://www.ncbi.nlm.nih.gov/pubmed/1997097
_version_ 1782134983322763264
author Thomas, G. A.
Williams, D.
Williams, E. D.
author_facet Thomas, G. A.
Williams, D.
Williams, E. D.
author_sort Thomas, G. A.
collection PubMed
description Longterm goitrogen administration to rodents is well known to result in multiple proliferative lesions of the thyroid. The regression of these lesions on withdrawal of goitrogen has led to their neoplastic nature being questioned, and they have been regarded as 'nodules' rather than as true tumours. We have induced multiple thyroid lesions by the combined use of high dose radiation as a mutagen, together with goitrogen administration to induce prolonged TSH growth stimulation. G6PD histochemistry was used in heterozygous G6PD deficient female mice to show that all the thyroid lesions induced by this regime were monophenotypic, and therefore monoclonal in origin. The great majority of induced tumours were adenomas, a minority were carcinomas. The number of carcinomas observed was significantly lower in a group of animals from which goitrogen was withdrawn for 4 weeks prior to killing, when compared to animals killed while on goitrogen treatment. Both adenomas and carcinomas, including areas of intravascular tumour, showed morphological features of regression on withdrawal of the goitrogen. There are three key cellular changes which must occur in spontaneous thyroid carcinogenesis--escape from a growth limiting mechanism, acquisition of TSH independent growth and acquisition of invasiveness. In the natural selection of mutations or epimutations during carcinogenesis, prolonged high levels of TSH are likely to remove any selective advantage from mutations that lead to TSH independent growth. Tumours induced by a regime including prolonged goitrogen treatment may therefore develop following two rather than three key stages. They will occur with an increased frequency relative to lesions observed in spontaneous carcinogenesis, but will retain TSH dependency. We speculate that several mechanisms may lead to loss of the growth limiting mechanism, including translocation of an oncogene to the region of a TSH induced promoter. Other carcinogenic regimes may also increase the yield of tumours by creating conditions which reduce the number of essential steps required for carcinogenesis, and may involve translocation to a carcinogen inducible promoter. IMAGES:
format Text
id pubmed-1971777
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19717772009-09-10 Reversibility of the malignant phenotype in monoclonal tumours in the mouse. Thomas, G. A. Williams, D. Williams, E. D. Br J Cancer Research Article Longterm goitrogen administration to rodents is well known to result in multiple proliferative lesions of the thyroid. The regression of these lesions on withdrawal of goitrogen has led to their neoplastic nature being questioned, and they have been regarded as 'nodules' rather than as true tumours. We have induced multiple thyroid lesions by the combined use of high dose radiation as a mutagen, together with goitrogen administration to induce prolonged TSH growth stimulation. G6PD histochemistry was used in heterozygous G6PD deficient female mice to show that all the thyroid lesions induced by this regime were monophenotypic, and therefore monoclonal in origin. The great majority of induced tumours were adenomas, a minority were carcinomas. The number of carcinomas observed was significantly lower in a group of animals from which goitrogen was withdrawn for 4 weeks prior to killing, when compared to animals killed while on goitrogen treatment. Both adenomas and carcinomas, including areas of intravascular tumour, showed morphological features of regression on withdrawal of the goitrogen. There are three key cellular changes which must occur in spontaneous thyroid carcinogenesis--escape from a growth limiting mechanism, acquisition of TSH independent growth and acquisition of invasiveness. In the natural selection of mutations or epimutations during carcinogenesis, prolonged high levels of TSH are likely to remove any selective advantage from mutations that lead to TSH independent growth. Tumours induced by a regime including prolonged goitrogen treatment may therefore develop following two rather than three key stages. They will occur with an increased frequency relative to lesions observed in spontaneous carcinogenesis, but will retain TSH dependency. We speculate that several mechanisms may lead to loss of the growth limiting mechanism, including translocation of an oncogene to the region of a TSH induced promoter. Other carcinogenic regimes may also increase the yield of tumours by creating conditions which reduce the number of essential steps required for carcinogenesis, and may involve translocation to a carcinogen inducible promoter. IMAGES: Nature Publishing Group 1991-02 /pmc/articles/PMC1971777/ /pubmed/1997097 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Thomas, G. A.
Williams, D.
Williams, E. D.
Reversibility of the malignant phenotype in monoclonal tumours in the mouse.
title Reversibility of the malignant phenotype in monoclonal tumours in the mouse.
title_full Reversibility of the malignant phenotype in monoclonal tumours in the mouse.
title_fullStr Reversibility of the malignant phenotype in monoclonal tumours in the mouse.
title_full_unstemmed Reversibility of the malignant phenotype in monoclonal tumours in the mouse.
title_short Reversibility of the malignant phenotype in monoclonal tumours in the mouse.
title_sort reversibility of the malignant phenotype in monoclonal tumours in the mouse.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971777/
https://www.ncbi.nlm.nih.gov/pubmed/1997097
work_keys_str_mv AT thomasga reversibilityofthemalignantphenotypeinmonoclonaltumoursinthemouse
AT williamsd reversibilityofthemalignantphenotypeinmonoclonaltumoursinthemouse
AT williamsed reversibilityofthemalignantphenotypeinmonoclonaltumoursinthemouse